Skip to main content

Table 4 Adverse events with an incidence > 1

From: Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: Phase III study results

Adverse event, n (%) Placebo
(n = 208)
Formoterol 4.5 μg bid (n = 206) Formoterol 9 μg bid (n = 199)
Nasopharyngitis 20 (9.6) 24 (11.7) 25 (12.6)
COPD exacerbation 17 (8.2) 10 (4.9) 8 (4.0)
Bronchitis complication 2 (1.0) 1 (0.5) 7 (3.5)
Pneumonia 0 2 (1.0) 3 (1.5)
Ill-defined disorder 2 (1.0) 2 (1.0) 1 (0.5)
Back pain 3 (1.4) 0 1 (0.5)
Dizziness 1 (0.5) 2 (1.0) 1 (0.5)
Glucose present in urine 2 (1.0) 2 (1.0) 0